S. 5029, introduced in the United States Senate, aims to modify the Social Security Act to create an exception for small biotech companies from being included in the Medicare drug price negotiation program. The bill specifically targets companies that focus heavily on...
Simple Explanation
S. 5029 is a bill that says small companies making new medicines don't have to lower their prices for Medicare if they spend a lot of money on inventing and testing new drugs.